Boulder, Colorado – November 7, 2019 - Bolder BioTechnology is pleased to announce that three scientific presentations describing use of the company’s novel interleukin-11 analog BBT-059 to treat acute radiation syndrome were given at the Radiation Research Society annual meeting held November 3-6, 2019 in San Diego, CA.
An invited oral presentation entitled “Pegylated IL-11 (BBT-059): A novel radiation countermeasure for hematopoietic acute radiation syndrome” was given by Vidya Kumar, Ph.D. of the Armed Forces Radiobiology Research Institute, Uniformed Services University of the Health Sciences, Bethesda, MD.
A poster entitled “Delayed effects of acute radiation exposure in a hematopoietic acute radiation syndrome mouse model” was presented by Neel K. Sharma, Shukla Biswas, Vidya Kumar, Gregory Holmes-Hampton, and Sanchita Ghosh of the Armed Forces Radiobiology Research Institute, Uniformed Services University of the Health Sciences and George N. Cox of Bolder Biotechnology.
A poster entitled “BBT-059, a novel prophylactic radiation countermeasure as well as a mitigator for acute radiation injury” was presented by Gregory Holmes-Hampton, Vidya P. Kumar, Shukla Biswas, Neel K. Sharma, Sasha Stone, and Sanchita P. Ghosh of the Armed Forces Radiobiology Research Institute, Uniformed Services University of the Health Sciences and Christine Fam and George Cox of Bolder Biotechnology.
